Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 5/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 4/20 | 1.00 |
| ▸ | F10 | P00742 | 2/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | F2 | P00734 | 7/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.55 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MASP2 | O00187 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | PLG | P00747 | 2/20 | 0.53 |
| ▸ | C1S | P09871 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717268 | 0.82 | PRSS1 (0.70) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL20610488 | 0.81 | PRSS1 (0.68) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL537030 | 0.81 | LMNA (0.77) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL2800579 | 0.80 | PRSS1 (0.67) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL49594 | 0.80 | LOXL2 (1.00) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL1696572 | 0.78 | PRSS1 (0.64) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL322008 | 0.78 | LOXL2 (0.95) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL1587085 | 0.78 | PRSS1 (0.64) | PRSS1PRSS3PRSS2F10LOXL2 | |
| Hydrochloric Acid SCHEMBL1981173 | 0.78 | LOXL2 (0.95) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL6484071 | 0.78 | PRSS1 (0.64) | PRSS1PRSS3PRSS2F10LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279664-A | FOLR1 binding agents, conjugates thereof, and methods of use thereof | 普方生物制药美国公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230159441-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | 3I, LP | 2023-05-25 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220175699-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | 3I, LP | 2022-06-09 | — | — | US | disclosed |
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-2683394-B1 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2216047-A1 | REGULATOR FOR SIGNALING OF TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | National University Corporation Tokyo Medical and Dental University (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2168600-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CEREBRAL ANEURYSM | Nippon Chemiphar Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-6689785-B2 | USEFUL PARTICULARLY AS REMEDIES FOR BONE DISEASES AND ARTHRITIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-02-10 | — | — | US | disclosed |
| EP-1342720-A2 | Epoxysuccinamide derivatives | NIPPON CHEMIPHAR CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1022276-B1 | EPOXYSUCCINAMIDE DERIVATIVES | NIPPON CHEMIPHAR CO (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-6387908-B1 | BONE DISORDERS; ANTIARTHRITIC AGENTS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-1022276-A1 | EPOXYSUCCINAMIDE DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | PRSS1 96/4885PRSS3 150/4885PRSS2 131/4885 |
| US-20230159441-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | CES2, ACHE, COMT | PRSS1 63/4885PRSS3 61/4885PRSS2 55/4885 |
| US-20100331545-A1 | REGULATOR FOR SIGNALING TOLL-LIKE RECEPTOR, WHICH COMPRISES CATHEPSIN INHIBITOR AS ACTIVE INGREDIENT | TLR1, TLR7, TLR6 | PRSS1 463/4885PRSS3 623/4885PRSS2 482/4885 |
| US-20220175699-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | ACHE, DNPEP, ACE | PRSS1 35/4885PRSS3 34/4885PRSS2 37/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS3 646/4885PRSS2 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.